Stay updated with breaking news from Program On Regulation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.
Three experts have now resigned from a Food and Drug Administration advisory committee after the agency approved an Alzheimer's drug called Aduhelm
In his resignation letter, Dr. Aaron Kesselheim calls it "probably the worst drug approval decision in recent U.S. history." An FDA official says the agency found the benefits outweighed the risks.
Three experts have now resigned from a Food and Drug Administration advisory committee after the agency approved an Alzheimer's drug called Aduhelm
E-Mail WHO Benjamin Rome, MD, Instructor of Medicine at Harvard Medical School and researcher in the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital; corresponding author of a paper published in WHAT When drug manufacturers raise the list price for brand-name prescription drugs, do patients' out-of-pocket costs rise too? A new study published in JAMA Network Open by Dr. Benjamin Rome and colleagues in the Brigham's Division of Pharmacoepidemiology and Pharmacoeconomics finds that more than ...